F. Azarbayjani

发表

Embryonic Arrhythmia by Inhibition of HERG Channels: A Common Hypoxia‐related Teratogenic Mechanism for Antiepileptic Drugs?

F. Azarbayjani, B. Danielsson, 2002, Epilepsia.

Common Mechanism for Teratogenicity of Antiepileptic Drugs: Drug-Induced Embryonic Arrhythmia and Hypoxia-Reoxygenation Damage

F. Azarbayjani, 2001 .

Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage.

F. Azarbayjani, B. Danielsson, A. Sköld, 2001, Current pharmaceutical design.

Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments

M. Stridsberg, R. Christofferson, D. Fuchs, 2009, Journal of Translational Medicine.

Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance

C. Sundberg, R. Christofferson, D. Fuchs, 2010, International journal of cancer.

Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage.

F. Azarbayjani, B. Danielsson, Bengt Danielsson, 2001, Teratology.

Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: a common teratogenic mechanism for antiepileptic drugs?

F. Azarbayjani, B. Danielsson, 1998, Teratology.

Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation.

W. Webster, F. Azarbayjani, B. Danielsson, 1997, Teratology.

The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis.

R. Christofferson, F. Azarbayjani, Å. Svensson, 2008, Anticancer research.

Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism.

C. Danielsson, F. Azarbayjani, B. Danielsson, 2005, Birth defects research. Part A, Clinical and molecular teratology.

Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to Fetal Hydantoin Syndrome in rats.

W. Webster, F. Azarbayjani, B. Danielsson, 2000, Toxicology and applied pharmacology.

Polytherapy with hERG-blocking antiepileptic drugs: increased risk for embryonic cardiac arrhythmia and teratogenicity.

C. Danielsson, F. Azarbayjani, B. Danielsson, 2007, Birth defects research. Part A, Clinical and molecular teratology.

Increased susceptibility to phenytoin teratogenicity: excessive generation of reactive oxygen species or impaired antioxidant defense?

L. Borg, F. Azarbayjani, B. Danielsson, 2006, Basic & clinical pharmacology & toxicology.

The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients.

A. Larsson, F. Hedborg, Å. Jakobson, 2009, Anticancer research.

Angiogenesis can be reduced without significant reduction of tumor growth.

R. Christofferson, D. Fuchs, F. Azarbayjani, 2007, Anticancer research.

Digoxin inhibits neuroblastoma tumor growth in mice.

Taro Matsumoto, R. Christofferson, F. Azarbayjani, 2005, Anticancer research.

The Anti-VEGF Antibody Bevacizumab Potently Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts

R. Christofferson, D. Fuchs, F. Azarbayjani, 2006, Pediatric Research.

Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance

C. Sundberg, R. Christofferson, D. Fuchs, 2010, International journal of cancer.